BIOC Quote, Trading Chart, Biocept Inc.
home / stock / bioc / bioc quote
$1.45 Last:
3.57% Change Percent:
$1.4 Open:
$1.45 Previous Close:
$1.46 High:
$1.38 Low:
68,007 Volume:
05/27/2022 04:53:29 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
BIOC Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2022-05-27 | 1.4 | 1.45 | 1.46 | 1.38 | 68,007 |
| 2022-05-26 | 1.39 | 1.4 | 1.47 | 1.38 | 58,970 |
| 2022-05-25 | 1.37 | 1.37 | 1.4 | 1.35 | 113,750 |
| 2022-05-24 | 1.42 | 1.405 | 1.4399 | 1.33 | 102,436 |
| 2022-05-23 | 1.46 | 1.48 | 1.62 | 1.4242 | 321,140 |
| 2022-05-20 | 1.49 | 1.44 | 1.4935 | 1.43 | 32,192 |
| 2022-05-19 | 1.4 | 1.49 | 1.49 | 1.4 | 46,736 |
| 2022-05-18 | 1.56 | 1.42 | 1.58 | 1.4 | 109,118 |
| 2022-05-17 | 1.57 | 1.54 | 1.6299 | 1.4738 | 117,807 |
| 2022-05-16 | 1.58 | 1.55 | 1.64 | 1.55 | 66,832 |
| 2022-05-13 | 1.52 | 1.54 | 1.57 | 1.4587 | 54,781 |
| 2022-05-12 | 1.5 | 1.43 | 1.56 | 1.43 | 103,937 |
| 2022-05-11 | 1.62 | 1.54 | 1.7 | 1.54 | 107,855 |
| 2022-05-10 | 1.65 | 1.62 | 1.69 | 1.6119 | 66,911 |
| 2022-05-09 | 1.58 | 1.65 | 1.75 | 1.58 | 113,648 |
| 2022-05-06 | 1.65 | 1.67 | 1.73 | 1.65 | 73,548 |
| 2022-05-05 | 1.71 | 1.7 | 1.73 | 1.62 | 56,897 |
| 2022-05-04 | 1.6 | 1.73 | 1.75 | 1.54 | 91,969 |
| 2022-05-03 | 1.65 | 1.59 | 1.73 | 1.585 | 79,829 |
| 2022-05-02 | 1.54 | 1.62 | 1.64 | 1.54 | 27,442 |
News, Short Squeeze, Breakout and More Instantly...
-
Net revenues of $19.9 million up 12% over Q1 2021 CNSide™ assay volume up 219% over Q1 2021 and up 70% over Q4 2021 Expanded CNSide customer base with additional oncologists from six leading cancer centers Previews re-focused and rationalized strategy ...
-
Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022. The delay is related to the ongoing accounting review of Biocept&#...
-
Fourth quarter net revenues of $14.0 million driven by RT-PCR COVID-19 testing volume Full year net revenues of $61.2 million increased 123% over the prior year Positive operating cash flow for 2021 of $3.7 million Cash and cash equivalents at 2021 year-end o...